[go: up one dir, main page]

SU839547A1 - Method of obtaining leukocytic interferon - Google Patents

Method of obtaining leukocytic interferon Download PDF

Info

Publication number
SU839547A1
SU839547A1 SU792750539A SU2750539A SU839547A1 SU 839547 A1 SU839547 A1 SU 839547A1 SU 792750539 A SU792750539 A SU 792750539A SU 2750539 A SU2750539 A SU 2750539A SU 839547 A1 SU839547 A1 SU 839547A1
Authority
SU
USSR - Soviet Union
Prior art keywords
interferon
obtaining
expand
virus
incubated
Prior art date
Application number
SU792750539A
Other languages
Russian (ru)
Inventor
Валентин Дмитриевич Соловьев
Всеволод Иванович Огарков
Виктор Исаакович Марченко
Лариса Александровна Монастырева
Александр Васильевич Киктенко
Владимир Викторович Парфенов
Ирина Ивановна Бухарова
Нина Константиновна Преображенская
Original Assignee
Всесоюзный Научно-Исследовательскийинститут Биологического Приборострое-Ния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Всесоюзный Научно-Исследовательскийинститут Биологического Приборострое-Ния filed Critical Всесоюзный Научно-Исследовательскийинститут Биологического Приборострое-Ния
Priority to SU792750539A priority Critical patent/SU839547A1/en
Application granted granted Critical
Publication of SU839547A1 publication Critical patent/SU839547A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

(54) СПОСОБ ПОЛУЧЕНИЯ ЛЕЙКОЦИТАРНОГО ИНТЕРФЕРОНА(54) METHOD FOR OBTAINING LEUKOCITARNY INTERFERON

с т евиной лейкоцитарный интерферон в количестве 100 ед. на 1 мл суспензии. Смесь инкубируют 2ч при затем центрифугируют дл  отделени  клеток от среды, клеки вновь суспензируют в свежей среде 199 с 10%-ной АМЖ, после чего в суспензию внос т вирус-ин .:дуктор. Титр ВБН определ ют предварительно в культуре куриных фибробластов .with t evinous leukocyte interferon in the amount of 100 units. on 1 ml of suspension. The mixture is incubated for 2 hours, then centrifuged to separate the cells from the medium, the glue is re-suspended in fresh medium 199 with 10% AMJ, after which the virus-in. Suspension is added to the suspension. VBN titer is pre-determined in a chicken fibroblast culture.

на I И этапе Определ ют антивирусную активность. Двухкратные разведени  интерфероносодержаадей жидкости внос т в пробирки с трехдневной культурой диплоидных.клеток человека и через 1&-20 ч инкубации при в те же пробирки внос т вирус-индикатор (вирус везикул рного стоматика ВВС, штамм Индиана ) в дозе 100 unflggHa пробирку. Через 48 ч инкубировани  при ,in stage I and stage Antiviral activity is determined. Twofold dilutions of the interferon-containing liquid are introduced into test tubes with a three-day culture of human diploid cells and after 1 & 20 h of incubation, an indicator virus (the air force vesicular dental virus, Indiana strain) is introduced in the same test tube at a dose of 100 unflggHa tube. After 48 h of incubation at

при условии наступлени  полной дегенерации клеток в контрольных пробирках с культурой ткани, не обработанной интерференом, но инфицированной вирусом, определ ют последнее разведение интерферона, защитившее клетки от вирусной деструкции . Это разведение принимают за титр интерферона и выражают его в единицах ме хдународного стандарта Б 69/19.subject to the onset of complete cell degeneration in control tubes with a tissue culture that was not treated with an interference, but infected with a virus, the last dilution of interferon was determined, which protected the cells from viral destruction. This dilution is taken as an interferon titer and expressed in units of international standard B 69/19.

Средний титр свиного лейкоцитарного интерферона в культуре диплоидных клеток человека 400М.ед/ в том случае, если интерферон получают без применени  прайминг-метода , а при использовании его 10000 М.ед/мл. The average titer of porcine leukocyte interferon in human diploid cell culture is 400M. Units / if interferon is obtained without the priming method, and when using it is 10,000 M. units / ml.

В таблице представлена сравнителна , характеристика свиного и человеческого лейкоцитарного интерфероНОВ .The table shows the comparative characteristics of swine and human leukocyte interferons.

1333+4201333 + 420

Claims (1)

Свиньи Предлагаемый способ позвол ет п чить интерферон, активный у челове ка, повысить качество интерферона за счет снижени  содержани  балластных белков и расширить сьарьевую базу. Формула изобретени  Способ получени  лейкоцитарного интерферона I путем заршхени  лей8 ,1±0,58 4835+814 0,70+0,12 крови вирусом-индуктором с Доследующей инкубацией и вьщелёниSM целевого продукта, отличающийс  тем, что, с целью расширени  сырьевой базы, дл  заражени  используют лейкоциты крови свиней и инкубируют в среде, содержащей амниотическую жидкость. Источники информации, прин тые во внимание при экспертизе 1. Авторское свидетельство СССР № 297296, кл. С 12 К 5/00, 1970.Pigs The proposed method allows the production of interferon, which is active in humans, to improve the quality of interferon by reducing the content of ballast proteins and expand the source base. The invention of the method of obtaining leukocyte interferon I by zeshenia leu8, 1 ± 0.58 4835 + 814 0.70 + 0.12 blood by an inducer virus with a further next incubation and an increase of the target product, characterized in that, in order to expand the raw material base, contamination using porcine leukocytes and incubated in medium containing amniotic fluid. Sources of information taken into account during the examination 1. USSR Author's Certificate No. 297296, cl. From 12 to 5/00, 1970.
SU792750539A 1979-04-06 1979-04-06 Method of obtaining leukocytic interferon SU839547A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU792750539A SU839547A1 (en) 1979-04-06 1979-04-06 Method of obtaining leukocytic interferon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU792750539A SU839547A1 (en) 1979-04-06 1979-04-06 Method of obtaining leukocytic interferon

Publications (1)

Publication Number Publication Date
SU839547A1 true SU839547A1 (en) 1981-06-23

Family

ID=20821146

Family Applications (1)

Application Number Title Priority Date Filing Date
SU792750539A SU839547A1 (en) 1979-04-06 1979-04-06 Method of obtaining leukocytic interferon

Country Status (1)

Country Link
SU (1) SU839547A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983001899A1 (en) * 1981-12-01 1983-06-09 BÉLADI, Ilona Process for the production of human gamma-interferon

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983001899A1 (en) * 1981-12-01 1983-06-09 BÉLADI, Ilona Process for the production of human gamma-interferon

Similar Documents

Publication Publication Date Title
US4376821A (en) Production of human IFN-gamma (immune) interferon
EP0253887B1 (en) Low dosage of interferon to enhance vaccine efficiency
Levin et al. Evaluation of the human interferon system in viral disease
CN1098103C (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
Kobayashi et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.
Rosenberg et al. In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus
US4376822A (en) Production of human IFN- γ (immune) interferon
Zink et al. Pathogenesis of visna/maedi and caprine arthritis-encephalitis: new leads on the mechanism of restricted virus replication and persistent inflammation
Vilček et al. Superinduction of interferon with metabolic inhibitors: possible mechanisms and practical applications
EP0017570B1 (en) Process for the preparation of interferon and culture medium composition used in it
OLESZAK et al. Platelet-derived growth factor (PDGF) inhibits antiviral and anticellular action of interferon in synchronized mouse or human cells
Lehmann et al. Infection of macrophages by influenza A virus: characteristics of tumour necrosis factor-α (TNFα) gene expression
US4614651A (en) Interferon epsilon
JPS6154040B2 (en)
Chen et al. Synergistic anti-herpes effect of TNF-α and IFN-γ in human corneal epithelial cells compared with that in corneal fibroblasts
Einhorn et al. Production and characterization of interferon from endothelial cells
SU839547A1 (en) Method of obtaining leukocytic interferon
CN1134537C (en) Separation, extracorporeal culture, preparation and application of human primitive mesenchymal stem cell population
Stewart et al. Relative antiviral resistance induced in homologous and heterologous cells by cross-reacting interferons
EP0048283B1 (en) Virus-inhibiting substance and process for preparing the same
NO173144B (en) PROCEDURE FOR THE PREPARATION OF INTERFERON GAMES
FI941920A (en) Method and composition for determining the immunological activity of bioactive substances
Ohmann et al. A neutrophil-derived antiviral protein: induction requirements and biological properties
JP2001000179A (en) Inactivation of virus
Hammar et al. Induction of tubuloreticular structures in cultured human endothelial cells by recombinant interferon alfa and beta